Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07510828 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

Name: PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors — clinical trial record (NCT07510828)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PRISM-NK

StatusRecruiting

PhasePhase 1/2

SponsorBeijing Biotech

Started2026-03-02

View on ClinicalTrials.gov ↗

Beijing Biotech

32 trials monitored

See all monitored trials

This Phase 1/2, open-label, biomarker-guided platform study evaluates the safety, tolerability, and preliminary anti-tumor activity of banked allogeneic donor-derived chimeric antigen receptor natural killer (CAR-NK) cells in adults with advanced solid tumors. During screening, tumor antigen profiling is performed using tissue biopsy and/or liquid biopsy (circulating tumor DNA and/or circulating tumor cells). Participants are assigned to receive either a single-target CAR-NK product (matched to the dominant tumor antigen) or a dual-target CAR-NK product (matched to two co-expressed antigens) to reduce the risk of antigen escape.

Trial Details

NCT Number	NCT07510828
Lead Sponsor	Beijing Biotech
Conditions	Advanced or Metastatic Solid Tumors
Enrollment	60 participants
Start Date	2026-03-02
Primary Completion	2027-03-14 (estimated)
Study Completion	2028-04-17 (estimated)
Updated on ClinicalTrials.gov	2026-04-06